Clinical Trials Logo

Oligospermia clinical trials

View clinical trials related to Oligospermia.

Filter by:

NCT ID: NCT04554030 Recruiting - Sperm Count, Low Clinical Trials

Impact of Immunotherapy on the Sperm Count of Patients With Cancer

Start date: January 2, 2020
Phase:
Study type: Observational

Cancer is a public health problem. In recent years, oncology has been revolutionized with the advent of new treatments for different tumor models, mainly immunotherapy directed against cell cycle control points. Numerous inhibitory pathways are incorporated into the immune system to maintain tolerance and homeostasis, and these are collectively known as immunological checkpoints. The main function of immunological checkpoints is to protect tissues from damage when the immune system is responding to pathogens and maintain tolerance to self antigens (ie, prevent autoimmunity). This is mainly achieved by down-regulation of T cell activation or effector functions. There is increasing evidence to show that a primary mechanism by which tumors evade the immune system is through the participation of immunological checkpoints. This has stimulated the development of many novel agents that modulate immunological checkpoints or other costimulatory receptors. CTLA-4 is the first receptor of the checkpoint that is successfully selected as immunotherapy. Ipilimumab, an anti-CTLA-4 monoclonal antibody, was the first immunological checkpoint inhibitor to receive FDA approval for the treatment of advanced melanoma. On the other hand, PD-1 is another receptor for the immune control point, and its ligands, the programmed cell death ligand 1 (PD-L1) and PD-L2, also resulted in important therapeutic advances in cancer immunotherapy. Unlike CTLA-4, PD-1 is widely expressed and can be found in, in addition to T cells, in B cells and natural killer (NK) cells. The main function of PD-1 is to limit the activity of T cells in peripheral tissues during an inflammatory immune response. The tumors can exploit this control point, expressing the ligand PD-L1 and generating that the cytotoxic T lymphocytes and the NK cells are anergic and incapable of killing. This up-regulation mechanism of PD-L1 is known in tumors such as melanoma, lung and ovary. Several monoclonal antibodies directed to PD-1 have already received approvals for their clinical use as Nivolumab and Pembrolizumab.

NCT ID: NCT03634644 Recruiting - Clinical trials for Male Infertility Due to Hypospermatogenesis

Omega-3 PUFA for Treatment of Patients With Idiopathic Oligoasthenoteratospermia

Start date: November 8, 2017
Phase: Phase 1
Study type: Interventional

Investigators have previously found that sperm quality was not related to obesity indicators, such as body mass index (bmi), waist circumference, waist-hip ratio, girth ratio and serum lipid, but seminal plasma lipids could notably affect the sperm concentration, sperm progressive ratio(PR), sperm DNA fragmentation index (DFI). These results indicates that abnormal lipid metabolism in the male reproductive system may affect male fertility. It seems that the sperm fatty acid spectrum is associated with n-3 polyunsaturated fatty acids (PUFA) in dietary. Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) are the most common n-3 PUFA. Only plasma DHA/EPA may reflect the quantity of DHA/EPA in adults. Most research indicate that n-3 PUFA is the main polyunsaturated fatty acid in human sperm. It is well known that diets have great influence on the gut microbiota composition. Many researches have delineated the cause and effect relationship between disturbed gut microbes and diseases, such as irritable bowel syndrome, obesity, diabetes. The disturbed gut microbiota ecosystem may also lead to the intestinal mucosal permeability increasing, which may result in endotoxemia and a series of metabolic syndrome. N-3 polyunsaturated fatty acids may play an important role in regulating metabolism and physiological functions in the body. A clinical research found that both total n-3 PUFA and DHA serum levels were significantly correlated with microbiome alpha diversity. Therefore, investigators may try to figure out the influence of n-3 PUFA supplement on gut microbiota composition and whether the gut microbiota have influence on sperm parameters. So investigators apply for your permission to collected the fecal samples from the participants, which will be a meaningful work.

NCT ID: NCT02063256 Recruiting - Oligospermia Clinical Trials

7 NUTS Study. Diet Modification and Male Fertility.

Start date: May 2014
Phase: Phase 2/Phase 3
Study type: Interventional

Setting. Outpatient fertility clinic. Aim. Investigate if a modification in nutritional habits may improve in the short term the qualities of human sperm, testing two hypothesis: i) that adding to the diet a natural whole food rich in polyunsaturated fatty acids (PUFA) OR ii) that reducing the intake of saturated fatty acids and increasing the consumption of PUFA may affect beneficially sperm parameters. Population. N. 100 hypofertile male subjects attending a fertility clinic. Type of study. Interventional study. No drugs or pharmacologic supplementation will be required nor allowed. Two different type of intervention are scheduled: - Supplementation to western style diet with nuts, naturally rich in PUFA - Diet modification increasing intake of PUFA-rich foods and cutting the consumption of food rich in saturated fats. Protocol - Baseline visit and recruiting. - Informed consent - Randomized allocation to treatment group in a 1: 1 manner Blinding. Investigators deputed to sperm analysis and statistician are blinded as to type of intervention. Phases: - i) basal - ii) after 15 weeks That interval is chosen because encompasses an entire spermatogenesis cycle. Outcomes. Primary - sperm count, concentration,morphology and mobility. Secondary: - serum folate assay, - plasma PUFA (ALA, EPA, DHA) assay, - body weight and BMI variation Statistics. A comparison for all sperm parameters (count,concentration,morphologic abnormalities, mobility) will be carried out by an analysis within groups and within patient.

NCT ID: NCT01856361 Recruiting - Male Infertility Clinical Trials

Ramipril for the Treatment of Oligospermia

Start date: July 2013
Phase: N/A
Study type: Interventional

This is a randomized controlled trial to evaluate the effect of ramipril in stimulating and promoting sperm production in men with low sperm count. Ramipril is an Angiotensin Converting Enzyme Inhibitor (ACEI) currently used to treat high blood pressure. However, previous studies have shown that this class of medications can improve sperm parameters. The purpose of this study is to evaluate the efficacy of ramipril compared to placebo (Substance That is not known to have treatment effect), in improving sperm density in infertile men with documented low sperm count. This study will help us identify subjects that might benefit from treatment with this medication, and the effect it will have on sperm count, shape, and motility.